Swedish Innovations Showcase Advanced Technology Transforming Modern Industrial and Cell Therapy Sectors
Swedish leaders highlight integration of advanced technology in modern industrial work and cell therapy automation, showcasing innovation and market growth potential.
- • Carl Aschan, CEO of Sinf, stresses advanced technology's importance in modern industrial work.
- • AcouSort uses ultrasound and microfluidics to automate cell therapy processes, reducing costs and enhancing safety.
- • AcouSort employs an OEM strategy with ten partners integrating its modules into production systems.
- • AcouSort targets the blood cancer cell therapy market with a $300M addressable market by 2030.
- • Technology integration exemplifies Sweden's leadership at the intersection of industry and medical innovation.
Key details
Recent developments highlight the crucial role of advanced technology in Sweden's industrial and medical landscapes. Carl Aschan, CEO of Sinf since February 2025, emphasizes that today’s industrial work relies heavily on sophisticated technologies. Drawing from his diverse background and experience in multiple Swedish cities, Aschan underlines the future-focused vision for Swedish industry where advanced technology is integral to productivity and innovation (89419).
In parallel, AcouSort, a Swedish tech company, is pioneering acoustic fluidics technology that automates cell handling in advanced therapies using ultrasound and microfluidics. This innovation aims to reduce the high costs of cell therapy by automating manual, labor-intensive processes involved in cell preparation, significantly improving efficiency and patient safety. CEO Torsten Freltoft likened their products to the "shovels and pickaxes" of the industry, setting a new gold standard in automated sample preparation (89410).
AcouSort’s OEM strategy involves integrating disposable separation modules into partners’ production systems, enhancing rapid market scaling with ten active collaborations. A key milestone includes commercial use of their technology in a clinically approved blood gas analysis system, generating recurring revenues and building industry credibility. Their primary market focus is blood cancer therapies, valued at an estimated $300 million by 2030, with ambitions to secure a 5-10% market share and expand into solid tumor treatments, potentially multiplying market opportunities (89410).